echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Gan Lai Pharmaceutical's THRβ agonist phase I clinical trial in the United States achieved good top-line data

    Gan Lai Pharmaceutical's THRβ agonist phase I clinical trial in the United States achieved good top-line data

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 8th, Gan Lai Pharmaceutical, a wholly-owned subsidiary of Gerry Pharmaceuticals, announced that the liver-targeted prodrug ASC41 oral tablet healthy subjects drug interactions and the pharmacokinetics of non-alcoholic fatty liver disease (NAFLD) patients PK (Phase I clinical trials in the United States) achieved good top-line data


    The clinical study consists of two cohorts


    Drug interaction data showed that there was no clinically significant difference in the exposure of the active metabolite ASC41-A with or without itraconazole or phenytoin


    The study also showed that the pharmacokinetic characteristics of ASC41/ASC41-A were not significantly different between healthy subjects and NAFLD patients


    In addition, the pharmacokinetic results of the US study are comparable to those of the ASC41 China Phase I study, indicating that the drug does not have significant pharmacokinetic differences between the Chinese and American populations


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.